PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$1.18
Price-1.67%
-$0.02
$55.027m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$35.496m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.95
-
1y CAGR-
3y CAGR-
5y CAGR$22.362m
$47.029m
Assets$24.666m
Liabilities$18.961m
Debt40.3%
-0.5x
Debt to EBITDA-$34.153m
-
1y CAGR-
3y CAGR-
5y CAGR